ADCT:NYE-ADC Therapeutics SA (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.95

Change

-0.06 (-1.99)%

Market Cap

USD 0.29B

Volume

0.20M

Analyst Target

USD 53.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Address: BiopOle, Epalinges, Switzerland, 1066

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

-0.49 (-0.96%)

USD 5.14B
RCUS Arcus Biosciences Inc

-0.41 (-2.50%)

USD 1.58B
NUVB Nuvation Bio Inc

-0.02 (-0.85%)

USD 0.79B
DNA Ginkgo Bioworks Holdings

-0.17 (-2.12%)

USD 0.50B
ANRO Alto Neuroscience, Inc.

+0.02 (+0.50%)

USD 0.37B
CYBN Cybin Inc

-0.59 (-5.62%)

USD 0.23B
ANVS Annovis Bio Inc

-0.20 (-2.05%)

USD 0.13B
ARMP Armata Pharmaceuticals Inc

-0.01 (-0.27%)

USD 0.08B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.08B
OSTX OS Therapies Incorporated

+0.06 (+2.18%)

USD 0.07B

ETFs Containing ADCT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 77.71% 56% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.71% 56% F 92% A
Trailing 12 Months  
Capital Gain 339.58% 65% D 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 339.58% 65% D 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -18.74% 12% F 3% F
Dividend Return -18.74% 12% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 80.99% 50% F 10% F
Risk Adjusted Return -23.14% 21% F 11% F
Market Capitalization 0.29B 82% B 41% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.